<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4131">
  <stage>Registered</stage>
  <submitdate>21/10/2013</submitdate>
  <approvaldate>21/10/2013</approvaldate>
  <nctid>NCT01969162</nctid>
  <trial_identification>
    <studytitle>Tear Collection in Adult Volunteers</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>195263-008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Tear Sample Collection

All Participants - Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.


Treatment: surgery: Tear Sample Collection
Tear sample collection as per protocol. No investigational drug is administered in this study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tear Lipid Composition Profile - Basal (non-stimulated) tear samples were collected from one eye for lipid analysis. 13 different lipids classes were detected in individual tear samples. The concentration of each lipid class is reported in picomoles (pmole).</outcome>
      <timepoint>Day 1</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Adult volunteers without ocular disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Systemic medications that could affect eye health taken within 1 month of enrollment

          -  Eye infection or inflammation in either eye 3 months prior to screening

          -  History of herpes in either eye

          -  Diagnosis of dry eye or meibomian gland dysfunction

          -  Diagnosis of glaucoma

          -  Allergic conjunctivitis

          -  Use of rigid contact lenses within 1 year of screening

          -  Use of soft contact lenses within 1 week of enrollment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>35</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital> - Randwick</hospital>
    <postcode> - Randwick</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allergan</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This exploratory study will collect tear samples from adult volunteers for determining and
      quantifying tear composition profiles. No investigational drug will be administered in this
      study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01969162</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Allergan</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>